GS XJG (Tykerb 250 mg)
Generic Name: lapatinib
Pill with imprint GS XJG is Orange, Elliptical / Oval and has been identified as Tykerb 250 mg. It is supplied by GlaxoSmithKline.
Tykerb is used in the treatment of breast cancer, metastatic; breast cancer and belongs to the drug classes EGFR inhibitors, HER2 inhibitors. There is positive evidence of human fetal risk during pregnancy. Tykerb 250 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for GS XJG
Tykerb
- Generic Name
- lapatinib
- Imprint
- GS XJG
- Strength
- 250 mg
- Color
- Orange
- Size
- 20.00 mm
- Shape
- Elliptical / Oval
- Availability
- Prescription only
- Drug Class
- EGFR inhibitors, HER2 inhibitors
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- GlaxoSmithKline
- Inactive Ingredients
-
magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A potato, FD&C Yellow No. 6, hypromelloses, polyethylene glycol, polysorbate 80, titanium dioxide
Note: Inactive ingredients may vary.
Labelers / Repackagers
| NDC Code | Labeler / Repackager |
|---|---|
| 00173-0752 | GlaxoSmithKline |
| 00078-0671 | Novartis Pharmaceuticals Corporation |
More about Tykerb (lapatinib)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 1 Review
- Generic Availability
- Drug class: EGFR inhibitors
- FDA Approval History
Consumer resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
